Phase I drug combination trial design: Walking the tightrope

2009-09-20

Journal of Clinical Oncology , Volume 27 - Issue 27 p. 4441- 4443

Additional Metadata
Keywords	advanced cancer, cancer combination chemotherapy, cancer palliative therapy, cancer patient, cetuximab, cisplatin, clinical trial, docetaxel, drug safety, editorial, febrile neutropenia, fluorouracil, gastrointestinal toxicity, head and neck carcinoma, human, incidence, local therapy, maximum tolerated dose, phase 1 clinical trial, priority journal, squamous cell carcinoma, treatment outcome
Persistent URL	doi.org/10.1200/JCO.2009.23.6703, hdl.handle.net/1765/19623
Journal	Journal of Clinical Oncology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Hamberg, P., & Verweij, J. (2009). Phase I drug combination trial design: Walking the tightrope. Journal of Clinical Oncology, 27(27), 4441–4443. doi:10.1200/JCO.2009.23.6703

Publication